What is The Lowdown?
The Lowdown operates as a specialized platform provider dedicated to improving health outcomes for women through accessible, data-driven insights. By bridging the gap between patient experiences and clinical information, the company has carved out a significant niche in the femtech market. Its platform serves as a critical resource for users navigating complex health decisions, effectively positioning the firm as a leader in the digital health transformation. The company's focus on user-centric design and evidence-based content has enabled it to build a robust community, which remains a core asset in its ongoing market expansion and service development strategy.
How much funding has The Lowdown raised?
The Lowdown has raised a total of $2.5M across 1 funding round:
Angel/Seed
$2.5M
Angel/Seed (2022): $2.5M with participation from Speedinvest, Calm/Storm VC, and Nina Capital
Key Investors in The Lowdown
Speedinvest
Speedinvest is a venture capital fund with over 1B Euro allocated for investing in pre-Seed, Seed, and early-stage tech startups across Europe, focusing on sectors including Health Bio and SaaS.
Calm/Storm VC
Calm/Storm VC is a venture capital firm specializing in early-stage health and wellness technology investments, supporting founders who aim to disrupt traditional healthcare models.
Nina Capital
Nina Capital is a specialized venture capital firm focused on investing in health technology companies at the pre-seed and seed stages, specifically targeting need-driven founders in the IT healthcare space.
What's next for The Lowdown?
With this major enterprise-level funding, The Lowdown is expected to accelerate its product roadmap and expand its reach across international markets. The strategic allocation of capital will likely prioritize the enhancement of its digital infrastructure and the integration of advanced analytics to better serve its growing user base. As the company transitions into its next phase of growth, the focus will remain on scaling its operational capacity while maintaining the high standards of clinical integrity that have defined its brand. Investors are closely watching how the firm will leverage its current momentum to solidify its market position and drive long-term value in the evolving healthtech ecosystem.
See full The Lowdown company page
